Bortenat 3.5mg Injection

Bortenat 3.5mg Injection contains Bortezomib, a powerful proteasome inhibitor that plays a critical role in treating multiple myeloma and mantle cell lymphoma. Bortezomib disrupts the cancer cells’ protein degradation pathway, resulting in the accumulation of damaged proteins, which induces cell death and slows tumor growth.

Key Features:

• Contains Bortezomib, a highly effective chemotherapy agent
• Indicated for the treatment of multiple myeloma and mantle cell lymphoma
• Inhibits proteasome activity to trigger cancer cell death
• Delivered through injection for optimal therapeutic impact
• Often combined with other treatments for enhanced efficacy